These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 32193187

  • 41. Efficacy and survival of golimumab with and without methotrexate in patients with psoriatic arthritis: A retrospective study from daily clinical practice.
    Sharif K, Gendelman O, Langevitz P, Reitblat T, Watad A, Shoenfeld Y, Azuri J, Amital H, Bragazzi NL, Shovman O.
    Best Pract Res Clin Rheumatol; 2018 Oct; 32(5):692-700. PubMed ID: 31203927
    [Abstract] [Full Text] [Related]

  • 42. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, Perdok RJ, Sasso EH.
    Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
    [Abstract] [Full Text] [Related]

  • 43. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.
    Bingham CO, Weinblatt M, Han C, Gathany TA, Kim L, Lo KH, Baker D, Mendelsohn A, Westhovens R.
    J Rheumatol; 2014 Jun; 41(6):1067-76. PubMed ID: 24786931
    [Abstract] [Full Text] [Related]

  • 44. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.
    Baranauskaite A, Raffayová H, Kungurov NV, Kubanova A, Venalis A, Helmle L, Srinivasan S, Nasonov E, Vastesaeger N, RESPOND investigators.
    Ann Rheum Dis; 2012 Apr; 71(4):541-8. PubMed ID: 21994233
    [Abstract] [Full Text] [Related]

  • 45. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [Abstract] [Full Text] [Related]

  • 46. Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis.
    Coates LC, Merola JF, Mease PJ, Ogdie A, Gladman DD, Strand V, van Mens LJJ, Liu L, Yen PK, Collier DH, Kricorian G, Chung JB, Helliwell PS.
    Rheumatology (Oxford); 2021 Mar 02; 60(3):1137-1147. PubMed ID: 32864685
    [Abstract] [Full Text] [Related]

  • 47. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
    Bingham CO, Mendelsohn AM, Kim L, Xu Z, Leu J, Han C, Lo KH, Westhovens R, Weinblatt ME, GO-FURTHER Investigators.
    Arthritis Care Res (Hoboken); 2015 Dec 02; 67(12):1627-36. PubMed ID: 25623393
    [Abstract] [Full Text] [Related]

  • 48. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial.
    Mulder MLM, Vriezekolk JE, van Hal TW, Nieboer LM, den Broeder N, de Jong EMGJ, den Broeder AA, van den Hoogen FHJ, Helliwell PS, Wenink MH.
    Lancet Rheumatol; 2022 Apr 02; 4(4):e252-e261. PubMed ID: 38288921
    [Abstract] [Full Text] [Related]

  • 49. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.
    Kavanaugh A, McInnes IB, Krueger GG, Gladman D, Beutler A, Gathany T, Mack M, Tandon N, Han C, Mease P.
    Arthritis Care Res (Hoboken); 2013 Oct 02; 65(10):1666-73. PubMed ID: 23666608
    [Abstract] [Full Text] [Related]

  • 50. Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study.
    Coates LC, Helliwell PS.
    J Rheumatol; 2016 Feb 02; 43(2):356-61. PubMed ID: 26669913
    [Abstract] [Full Text] [Related]

  • 51. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.
    Genovese MC, Han C, Keystone EC, Hsia EC, Buchanan J, Gathany T, Murphy FT, Wu Z, Parasuraman S, Rahman MU.
    J Rheumatol; 2012 Jun 02; 39(6):1185-91. PubMed ID: 22505702
    [Abstract] [Full Text] [Related]

  • 52. Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial.
    Emery P, Fleischmann RM, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel B, Han C, Gathany TA, Xu S, Zhou Y, Leu JH, Hsia EC.
    Arthritis Care Res (Hoboken); 2016 Jun 02; 68(6):744-52. PubMed ID: 26474452
    [Abstract] [Full Text] [Related]

  • 53. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study.
    Huizinga TW, Conaghan PG, Martin-Mola E, Schett G, Amital H, Xavier RM, Troum O, Aassi M, Bernasconi C, Dougados M.
    Ann Rheum Dis; 2015 Jan 02; 74(1):35-43. PubMed ID: 25169728
    [Abstract] [Full Text] [Related]

  • 54. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.
    Barrera P, van der Maas A, van Ede AE, Kiemeney BA, Laan RF, van de Putte LB, van Riel PL.
    Rheumatology (Oxford); 2002 Apr 02; 41(4):430-9. PubMed ID: 11961174
    [Abstract] [Full Text] [Related]

  • 55. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial.
    Nam JL, Villeneuve E, Hensor EM, Wakefield RJ, Conaghan PG, Green MJ, Gough A, Quinn M, Reece R, Cox SR, Buch MH, van der Heijde DM, Emery P.
    Ann Rheum Dis; 2014 Jun 02; 73(6):1027-36. PubMed ID: 24618266
    [Abstract] [Full Text] [Related]

  • 56. Methotrexate achieves major cDAPSA response, and improvement in dactylitis and functional status in psoriatic arthritis.
    Appani SK, Devarasetti PK, Irlapati RVP, Rajasekhar L.
    Rheumatology (Oxford); 2019 May 01; 58(5):869-873. PubMed ID: 30590763
    [Abstract] [Full Text] [Related]

  • 57. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
    Huang F, Zhang FC, Bao CD, Tao Y, Gu JR, Xu JH, Zhu P, Xu HJ, Zhang ZY, Zhao DB, Wu DH.
    Zhonghua Nei Ke Za Zhi; 2009 Nov 01; 48(11):916-21. PubMed ID: 20079321
    [Abstract] [Full Text] [Related]

  • 58. TNFi-induced sustained clinical remission in peripheral spondyloarthritis patients cannot be maintained with a step-down strategy based on methotrexate.
    Carron P, De Craemer AS, Renson T, Colman R, Elewaut D, Van den Bosch F.
    Rheumatology (Oxford); 2021 Oct 02; 60(10):4880-4883. PubMed ID: 33471112
    [Abstract] [Full Text] [Related]

  • 59. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study.
    Mease PJ, Gladman DD, Keystone EC, Alefacept in Psoriatic Arthritis Study Group.
    Arthritis Rheum; 2006 May 02; 54(5):1638-45. PubMed ID: 16646026
    [Abstract] [Full Text] [Related]

  • 60. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
    Visvanathan S, Wagner C, Rojas J, Kay J, Dasgupta B, Matteson EL, Mack M, Baker DG, Rahman MU.
    J Rheumatol; 2009 Jul 02; 36(7):1371-9. PubMed ID: 19487269
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.